TG Therapeutics, Inc. (TGTX)
53.97
-2.03
(-3.62%)
USD |
NASDAQ |
Oct 16, 16:00
53.75
-0.22
(-0.41%)
After-Hours: 20:00
TG Therapeutics Free Cash Flow : 17.38M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.38M |
| March 31, 2026 | -14.19M |
| December 31, 2025 | -24.99M |
| September 30, 2025 | -70.24M |
| June 30, 2025 | -59.24M |
| March 31, 2025 | -61.10M |
| December 31, 2024 | -40.56M |
| September 30, 2024 | -28.11M |
| June 30, 2024 | 67.82M |
| March 31, 2024 | 20.28M |
| December 31, 2023 | -31.41M |
| September 30, 2023 | -42.08M |
| June 30, 2023 | -160.28M |
| March 31, 2023 | -167.39M |
| December 31, 2022 | -176.18M |
| September 30, 2022 | -239.30M |
| June 30, 2022 | -272.08M |
| March 31, 2022 | -283.31M |
| December 31, 2021 | -296.04M |
| September 30, 2021 | -261.23M |
| June 30, 2021 | -250.57M |
| March 31, 2021 | -234.10M |
| December 31, 2020 | -214.86M |
| September 30, 2020 | -193.11M |
| June 30, 2020 | -169.76M |
| Date | Value |
|---|---|
| March 31, 2020 | -161.76M |
| December 31, 2019 | -132.94M |
| September 30, 2019 | -136.21M |
| June 30, 2019 | -135.97M |
| March 31, 2019 | -134.31M |
| December 31, 2018 | -129.02M |
| September 30, 2018 | -117.17M |
| June 30, 2018 | -106.91M |
| March 31, 2018 | -99.53M |
| December 31, 2017 | -93.76M |
| September 30, 2017 | -88.95M |
| June 30, 2017 | -81.23M |
| March 31, 2017 | -67.28M |
| December 31, 2016 | -61.93M |
| September 30, 2016 | -57.77M |
| June 30, 2016 | -53.41M |
| March 31, 2016 | -52.79M |
| December 31, 2015 | -44.73M |
| September 30, 2015 | -46.97M |
| June 30, 2015 | -44.32M |
| March 31, 2015 | -35.64M |
| December 31, 2014 | -35.08M |
| September 30, 2014 | -24.87M |
| June 30, 2014 | -17.97M |
| March 31, 2014 | -16.96M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Krystal Biotech, Inc. | 257.78M |
| Vertex Pharmaceuticals, Inc. | 3.796B |
| SELLAS Life Sciences Group, Inc. | -28.42M |
| Travere Therapeutics, Inc. | 15.40M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |